# Micrima

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/micrima

- Industry: Medical Devices & Equipment
- Headquarters: Bristol, UK
- Website: www.micrima.com
- Total disclosed funding: $11M
- Latest round: Series B (Mar 26, 2018)
- Investors on record: 6

## About

Micrima Limited is focused on advancing breast cancer diagnostics through its innovative imaging technology. The company aims to enhance early detection and improve patient outcomes in breast health.Micrima Limited, founded in 2005, is headquartered in Bristol, UK, and specializes in breast cancer diagnostic solutions. The company has undergone a strategic shift to enhance its offerings in breast imaging. Notably, Micrima raised GBP 4.4 million in a Series B funding round on March 26, 2018, led by Technology Venture Partners, which values the company at GBP 25.59 million. Their operations have included a total of 6 deals, with no mention of subsidiaries or parent companies. The current CEO is Adrian Waller, whose background is integral to the company's vision.Micrima specializes in innovative breast cancer diagnostic solutions, primarily through its flagship offering, the Mi~Scan®. This technology provides detailed measurements of breast tissue properties, facilitating personalized imaging strategies and enhancing risk profiling for breast cancer. The Mi~Scan® empowers clinicians and women to enable earlier diagnosis, addressing issues of breast density that can obscure cancer detection. The company targets healthcare providers and institutions in the UK and Europe, with plans for expansion into other international markets as demand for advanced breast imaging solutions grows, serving a diverse client base that includes radiology departments and healthcare facilities.Micrima's revenue model is centered around the provision of its diagnostic services, involving direct sales of the Mi~Scan® technology to healthcare providers or service agreements that include ongoing technical support and training. The company engages in B2B transactions with hospitals and clinics, offering subscription-based access to software updates and clinical support, ensuring clients maximize their diagnostic systems. Pricing structures are tailored to meet the needs of healthcare organizations, providing various service tiers based on the volume of scans performed to develop a steady revenue stream.Micrima Limited plans to utilize recent funding to support its growth strategy, focusing on product development and market expansion. The company aims to enhance its Mi~Scan® technology and is exploring new geographical markets beyond the UK and Europe, with specific plans for international outreach driven by rising demand for advanced breast imaging solutions. The GBP 4.4 million raised in Series B funding will be instrumental in these initiatives, allowing the company to scale operations and invest in research and development.

## Funding rounds

- Series B, Mar 26, 2018, $6.2M — Technology Venture Partners, ACF Investors, VentureFounders
- Series B, Apr 5, 2016, $3.8M — Technology Venture Partners, YFM Equity Partners, Swarraton Partners, Parkwalk Advisors, ACF Investors
- Series B, Mar 20, 2012, $1.4M — Technology Venture Partners, YFM Equity Partners, Swarraton Partners

## Investors

- Technology Venture Partners — Series B
- YFM Equity Partners (https://capitalatlas.ai/funds/yfm-equity-partners) — Series B
- Swarraton Partners (https://capitalatlas.ai/funds/swarraton-partners) — Series B
- Parkwalk Advisors (https://capitalatlas.ai/funds/parkwalk-advisors) — Series B
- ACF Investors (https://capitalatlas.ai/funds/acf-investors) — Series B
- VentureFounders — Series B